blarcamesine   Click here for help

GtoPdb Ligand ID: 11586

Synonyms: AE-37 | AE37 | Anavex 2-73 | Anavex2-73 | THD-DP-FM
Compound class: Synthetic organic
Comment: Blarcamesine (Anavex2-73) is a Sigma-1 (σ1) protein agonist and muscarinic acetylcholine receptor modulator [6]. Anavex are investigating it for potential to slow progression in neurodegenerative conditions including Parkinson's and Alzheimer's diseases, and Rett syndrome [2]. Anticonvulsant, anti-amnesic, neuroprotective and antidepressant activities in response to blarcamesine have been identified in a number of animal models of neurodegenerative and neurodevelopmental conditions [3-6].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

blarcamesine is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 4
Topological polar surface area 12.47
Molecular weight 281.18
XLogP 3.63
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CN(CC1CCOC1(c1ccccc1)c1ccccc1)C
Isomeric SMILES CN(CC1CCOC1(c1ccccc1)c1ccccc1)C
InChI InChI=1S/C19H23NO/c1-20(2)15-18-13-14-21-19(18,16-9-5-3-6-10-16)17-11-7-4-8-12-17/h3-12,18H,13-15H2,1-2H3
InChI Key BOTHKNZTGGXFEQ-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Anavex have progressed ANAVEX2-73 to clinical evaluations in patients with neurodegenerative conditions including Parkinson's and Alzheimer's diseases, and Rett syndrome.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04304482 ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome Phase 2/Phase 3 Interventional Anavex Life Sciences Corp.
NCT04314934 OLE of Phase 2b/3 Study ANAVEX2-73-AD-004 Phase 2/Phase 3 Interventional Anavex Life Sciences Corp.
NCT04575259 OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001 Phase 2 Interventional Anavex Life Sciences Corp.
NCT02244541 Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease Phase 2 Interventional Anavex Life Sciences Corp. This 57 week trial was extended for an additional 208 weeks (NCT02756858) after meeting its primary safety endpoint. 1
NCT02756858 An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease Phase 2 Interventional Anavex Life Sciences Corp.